Rubicon Research Q4 FY26 Revenue Surges 43.5% YoY to ₹513.9 Crore, PAT Jumps 111.8%
Rubicon Research reported a 43.5% YoY revenue increase to ₹513.9 crore in Q4 FY26. PAT surged 111.8% YoY to ₹76.8 crore. Full-year revenue grew 36.6% to ₹1,754 crore, and PAT rose 83.6% to ₹246.7 crore. The company acquired Arinna Lifesciences for ₹176 crore and recommended a 150% dividend.
The significant increase in revenue and profit, along with a strategic acquisition, will likely have a substantial positive impact on the company's financial performance and market position.
The company reported strong year-on-year growth in revenue and profit, exceeding expectations. The recommended dividend and strategic acquisition further contribute to positive sentiment.
Rubicon Research Limited announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a significant 43.5% year-on-year increase in revenue from operations for Q4 FY26, reaching ₹5,139 million (₹513.9 crore), compared to ₹3,581 million (₹358.1 crore) in Q4 FY25. This growth was broad-based. For the full fiscal year FY26, revenue from operations grew by 36.6% to ₹17,540 million (₹1,754 crore) from ₹12,843 million (₹1,284.3 crore) in FY25.
Profit After Tax (PAT) for Q4 FY26 saw a substantial jump of 111.8% YoY, reaching ₹768 million (₹76.8 crore) from ₹362 million (₹36.2 crore) in the prior year. Full-year PAT grew by 83.6% to ₹2,467 million (₹246.7 crore) from ₹1,344 million (₹134.4 crore) in FY25. Earnings Per Share (EPS) for the quarter was ₹4.60, up 97.0% from ₹2.34 in Q4 FY25.
The company highlighted strong revenue visibility for the coming quarters and noted that approximately 98% of its revenue is USD denominated. USD revenue for Q4 FY26 was $56 million, a 35% increase YoY. The board has recommended a dividend of 150%, amounting to ₹1.50 per share.
Rubicon Research also detailed its strategic initiatives, including the acquisition of Arinna Lifesciences for ₹176 crore (85% stake), a CNS-focused Indian formulations company. The company continues to invest in R&D, with R&D expenses at 11.6% of operating revenue for Q4 FY26. The presentation also covered the company's robust pipeline of products, manufacturing capabilities, and market execution strategies, emphasizing its shift towards specialty and differentiated products.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.